Education
About Us
Working with TipRanks
Follow Us
CARGO Therapeutics, Inc. (CRGX)
:CRGX
RESEARCH TOOLSreports
CRGX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.00 - $25.45
Previous CloseN/A
Volume19.28K
Average Volume (3M)1.63M
Market Cap
$212.58M
Enterprise Value$181.26M
Total Cash (Recent Filing)$318.84M
Total Debt (Recent Filing)$30.45M
Price to Earnings (P/E)―
Beta1.31
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.66
Shares Outstanding46,113,354
10 Day Avg. Volume3,810,434
30 Day Avg. Volume1,626,937
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.78
Price to Sales (P/S)0.00
P/FCF Ratio-1.41
Enterprise Value/Market Cap0.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-87.95
Enterprise Value/Ebitda-0.29
Forecast
1Y Price Target
$5.00Price Target Upside8.46% Upside
Rating ConsensusHold
Number of Analyst Covering1
CARGO Therapeutics, Inc. News
PremiumCompany Announcements
CARGO Therapeutics Announces Merger with Concentra Biosciences
PremiumCompany Announcements
CARGO Therapeutics Transfers Lease to Dren Bio
PremiumCompany Announcements
CARGO Therapeutics Elects Directors at Annual Meeting
PremiumCompany Announcements
CARGO Therapeutics Announces Major Workforce ReductionBulls Say, Bears Say
Bulls Say
Advancement Of Tri-specific ProgramCargo will continue to advance CRG-023, its tri-specific CAR-T therapeutic candidate, into a Phase 1 dose escalation study.
Pipeline DevelopmentCargo plans to initiate enrollment for the Phase I study evaluating CRG-023, an autologous CAR-T cell therapy that expresses three fully human CAR molecules targeting CD19, CD20, and CD22.
Bears Say
Discontinuation Of Firi-cel TrialCRGX announced surprising and disappointing news and will discontinue the lead Phase II Firi-cel (CD22 CART) due to safety and durability.
Safety ConcernsSafety data showed 18% of patients developed immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome that were Grade 3 or higher, including both Grade 4 and 5.
Workforce ReductionCargo Therapeutics is implementing a workforce reduction of approximately 50% to preserve cash.
Ownership Overview
10.72% Insiders
24.12% Mutual Funds
<0.01% Other Institutional Investors
56.25% Public Companies and
Individual Investors
CRGX FAQ
What was CARGO Therapeutics, Inc.’s price range in the past 12 months?
CARGO Therapeutics, Inc. lowest stock price was $3.00 and its highest was $25.45 in the past 12 months.
What is CARGO Therapeutics, Inc.’s market cap?
CARGO Therapeutics, Inc.’s market cap is $212.58M.
When is CARGO Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CARGO Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is CARGO Therapeutics, Inc. overvalued?
According to Wall Street analysts CARGO Therapeutics, Inc.’s price is currently Undervalued.
Does CARGO Therapeutics, Inc. pay dividends?
CARGO Therapeutics, Inc. does not currently pay dividends.
What is CARGO Therapeutics, Inc.’s EPS estimate?
CARGO Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CARGO Therapeutics, Inc. have?
CARGO Therapeutics, Inc. has 46,113,354 shares outstanding.
What happened to CARGO Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CARGO Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CRGX
CARGO Therapeutics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.00 (8.46% Upside)
$5.00 (8.46% Upside)
Blogger Sentiment
Bullish
CRGX Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $112.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 10.9%
Last 30 Days ▼ 10.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.95%
12-Months-Change
Fundamentals
Return on Equity
-65.94%
Trailing 12-Months
Asset Growth
-14.32%
Trailing 12-Months
Company Description
CARGO Therapeutics, Inc.
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.
CRGX Stock 12 Month Forecast
Average Price Target
$5.00
▲(8.46%Upside)
Technical Analysis
Voyager Therapeutics
―
Checkpoint Therapeutics
―
COMPASS Pathways
―
Foghorn Therapeutics
―
4D Molecular Therapeutics
―